Overview

Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis

Status:
Completed
Trial end date:
2019-03-13
Target enrollment:
Participant gender:
Summary
The study is a randomized, double-blind, placebo-controlled, study that will be conducted at multiple centers in subjects with Cystic Fibrosis (CF) who are either homozygous for the F508del mutation or heterozygous with at least copy of the F508del mutation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Proteostasis Therapeutics, Inc.